enGene Therapeutics Inc. — Company profile
Healthcare · Biotechnology · Canada
Last price 1.53 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 102.53M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Details
| Name | enGene Therapeutics Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 82 |
| Founded | 1999 |
| Ceo | Ronald H. Cooper |
| Country | Canada |
| Exchange | NASDAQ |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| Isin | CA29286X1015 |
| Cusip | 29286X101 |
| Cik | 1980845 |
| Sic | 2836 |
| Share Class | Class A Shares |
Key executives
| Name | Title |
|---|---|
| Ronald H. W. Cooper | President, Chief Executive Officer and Director |
| Dr. William J. Grossman M.D., Ph.D. | Interim Chief Medical Officer and Director |
| Kathleen Richton | Senior Vice President of Finance, Principal Accounting and Financial Officer and Controller |
| Joan Connolly | Chief Technology Officer |
| Tara Place M.B.A. | Senior Vice President of Human Resources |
| Dr. Anthony T. Cheung Ph.D. | Consultant |
| Matthew Boyd | Chief Regulatory Officer |
| Jill Buck | Chief Development Officer |
| Amy Pott | Chief Global Commercialization Officer |
Contact
| Address | 4868 Rue Levy, Suite 220, Montreal, QC H4R 2P1, Canada |
| Phone | 514 332 4888 |
| Website | https://www.engene.com |